WHAT IS CLAIMED

1. A compound of formula (**I**)



(**I**)

wherein

A is **A1a** which is a 5- or 6-membered mono-heteroaryl ring containing one or two heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur; wherein at least one of the heteroatom members is nitrogen;

or **A** is **A1b** which is a 9- or 10-membered fused bicyclic-heteroaryl ring containing one to four heteroatom members selected from the group consisting of nitrogen, oxygen and sulphur, wherein at least two of the heteroatom members is nitrogen;

R^1 is selected from the group **R1e**, consisting of F;

R^2 is selected from the group **R2a**, consisting of H, halo, hydroxy, C_{1-6}-alkyl, C_{2-6}-alkynyl, C_{3-6}-cycloalkyl, 1-methyl-C_{3-6}-cycloalkyl, F_{1-9}-fluoro-C_{1-6}-alkyl, HO-C_{1-6}-alkyl, C_{1-6}-alkyloxy, C_{1-4}-alkyl-O-H_2CH_2C-O-, C_{3-6}-cycloalkyloxy, C_{3-6}-cycloalkyl-H_2C-O-, F_{1-9}-fluoro-C_{1-4}-alkyloxy, C_{1-6}-alkyl-O-C(O)-, H_2N-C(O)- and C_{1-6}-alkyl-NH-C(O)-;

R^3 is selected from the group **R3a**, consisting of H, C_{1-4}-alkyl, F_{1-9}-fluoro-C_{1-4}-alkyl and halo;

R^4 is selected from the group **R4a**, consisting of halo, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, -CN, C_{1-6}-alkyloxy, C_{1-6}-alkyl-O-C(O)-, F_{1-9}-fluoro-C_{1-4}-alkyl, F_{1-9}-fluoro-C_{1-4}-alkyloxy, C_{3-6}-cycloalkyloxy, C_{3-6}-cycloalkyl-H_2C-O-, benzyloxy, $(HO)(H_3C)_2$-C- and HO-$C(H_3C)_2H_2CH_2C$-O-;
or a salt thereof, particularly a pharmaceutically acceptable salt thereof.

2. The compound of formula (**I**) according to claim 1, wherein **A** is selected from the group **A5** consisting of pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, 2H-pyrazolo[3,4-b]pyridinyl and imidazo[1,2-a]pyrimidinyl;
or a salt thereof.

3. The compound of formula (**I**) according to any of claims 1 to 2, wherein **R^2** is **R2b**, consisting of H, halo, C_{1-4}-alkyl, C_{3-4}-cycloalkyl, F_{1-9}-fluoro-C_{1-6}-alkyl, 1-methyl-C_{3-6}-cycloalkyl, C_{1-4}-alkyloxy and C_{3-4}-cycloalkyloxy;
or a salt thereof.

4. The compound of formula (**I**) according to any of claims 1 to 3, wherein **R^4** is selected from the group **R4b**, consisting of halo, -CN, C_{1-4}-alkyl, C_{3-6}-cycloalkyl, C_{1-6}-alkyloxy, C_{1-6}-alkyl-O-C(O)-, F_{1-9}-fluoro-C_{1-4}-alkyl, F_{1-9}-fluoro-C_{1-4}-alkyloxy, C_{3-6}-cycloalkyloxy, C_{3-6}-cycloalkyl-H_2C-O-, benzyloxy, $(HO)(H_3C)_2$-C- and HO-$C(H_3C)_2H_2CH_2C$-O-;
or a salt thereof.

5. The compound of formula (**I**) according to any of claims 1 to 4 having formula (**1-c**)



(**I-c**)

or a salt thereof.

6. The compound of formula (**I**) according to any of claims 1 to 4 having formula (**1-f**)



(**I-f**)

or a salt thereof.

7. The compound of formula (**I**) according to any of claims 1 to 4 having formula (**1-j**)



(**I-j**)

or a salt thereof.

8. The compound of formula (**I**) according to any of claims 1 to 4 having formula (**1-n**)



(**I-n**)

or a salt thereof.

9. The compound of formula (**I**) according to claim 1, selected from the group consisting of


,

,

,

,


N
N
N
F
N
F
N
F
,

N
N
N
F
N
F
N
O
,


,

,

,

,

,

,


,

,

,

,

,

,



and



;

or a salt thereof.

10. A compound selected from the group consisting of



,



,


,

,

,

,

,

,



and 

;

or a salt thereof.

11. A pharmaceutically acceptable salt of a compound according to one or more of claims 1 to 10.

12. A pharmaceutical composition comprising one or more compounds according to one or more of claims 1 to 10, or pharmaceutically acceptable salts thereof, optionally together with one or more inert carriers and/or diluents.

13. A pharmaceutical composition comprising one or more compounds according to one or more of the claims 1 to 10, or pharmaceutically acceptable salts thereof, and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

14. The pharmaceutical composition according to claim 13 wherein the one or more additional therapeutic agents are selected from the group consisting of anticancer agents and antifibrotic agents.

15. The compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use as a medicament.

16. A compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use in the treatment of diseases, such as cancer or fibrotic diseases, and conditions associated with these diseases.

17. Use of a compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of diseases, such as cancer or fibrotic diseases, and conditions associated with these diseases.

18. A compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, fibrotic diseases, neurodegenerative diseases, atherosclerosis, infectious diseases, or chronic kidney diseases.

19. Use of a compound according to one or more of claims 1 to 10 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, fibrotic diseases, neurodegenerative diseases, atherosclerosis, infectious diseases, or chronic kidney diseases.